Under the patronage of Health Minister Dr. Tawfiq bin Fawzan Al-Rabiah, SPIMACO Addwaeih has signed an agreement with Amgen US Company to localize the marketing rights and transfer the technology of some manufacturing steps of a high quality biotechnology product that is used to treat immunological diseases, which comes in line with Saudi Arabia's Vision 2030 to encourage the localization of the high technology pharmaceutical industries and increase the local content. The agreement stipulated that SPIMACO Addwaeih obtains marketing and trademark rights for a high quality biotechnology product, and that SPIMACO Addwaeih is registered as the owner of marketing rights with the Saudi Food and Drug Authority (SFDA) in the Kingdom of Saudi Arabia. The product has also been registered with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and was successfully marketed in a large number of European countries. The agreement also stipulated that some manufacturing steps of this product to be transferred and localized to the company's factory in Qassim region. Within the plans, this product will be the beginning of a strategic alliance between the two companies to include more high-quality biotechnology products.
